A call for standardization due to CSF biomarker variability to ensure quality control
The CSF biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer’s disease research and patient management. However, there are large variations in biomarker measurements among and within laboratories.
